Product Description
Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Alvocidib)
Mechanisms of Action: CDK9 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Thromboembolism|Head and Neck Cancer|Prolymphocytic Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Squamous Cell Carcinoma|Multiple Myeloma|Peritoneal Cancer|Melanoma|Follicular Lymphoma|Multiple Sclerosis|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Lymphomatoid Granulomatosis|Large-Cell Immunoblastic Lymphoma|B-Cell Marginal Zone Lymphoma|Acute Myeloid Leukemia|Ovarian Cancer|Sezary Syndrome|Large-Cell Anaplastic Lymphoma|Immunoblastic Lymphadenopathy|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|Diffuse Large B-Cell Lymphoma|Pancreatic Cancer|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Lymphoma, B-Cell|Adenocarcinoma|Renal Cell Carcinoma|Kidney Cancer|Liver Cancer|Esophageal Cancer|Breast Cancer|Endometrial Cancer|Sarcoma|Acute Megakaryoblastic Leukemia|Acute Erythroblastic Leukemia|Prostate Cancer|Myelodysplastic Syndrome|Preleukemia|Acute Basophilic Leukemia|Acute Myelomonocytic Leukemia|Gastrointestinal Cancer|Acute Lymphoid Leukemia|Seminoma|Germinoma|Acute Monocytic Leukemia|Testicular Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Eosinophilic Leukemia|Hypereosinophilic Syndrome
Phase 1: Prolymphocytic B-Cell Leukemia|Thrombocytopenia|Anemia, Refractory|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Adenocarcinoma|Acute Eosinophilic Leukemia|Acute Myelomonocytic Leukemia|Lymphoma, B-Cell|Prolymphocytic Leukemia|Chronic Myeloid Leukemia|Blast Crisis|Acute Lymphoid Leukemia|Pancreatic Cancer|Neuroblastoma|Lymphoma, Non-Hodgkin|Oncology Solid Tumor Unspecified|Astrocytoma|Osteosarcoma|Medulloblastoma|Embryonal Rhabdomyosarcoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Liver Cancer|Hypothalamic Cancer|Kidney Cancer|Brain Stem Cancer|Wilms Tumor|Acute Basophilic Leukemia|Acute Myeloid Leukemia|Acute Megakaryoblastic Leukemia|Male Breast Cancer|Acute Erythroblastic Leukemia|Leukemia|Chronic Myelomonocytic Leukemia|Hypereosinophilic Syndrome|Acute Monocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Sarcoma, Ewing|Retinoblastoma|Optic Nerve Cancer|Optic Nerve Glioma|Cerebellar Cancer|Prostate Cancer|Primitive Neuroectodermal Tumors|Supratentorial Cancer|Soft Tissue Cancer|Lymphoid Leukemia|Peripheral Neuroectodermal Tumors, Primitive|Ependymoma|Kidney Diseases|Intestinal Cancer|Lymphoma|Non-Small-Cell Lung Cancer|Esophageal Cancer|Follicular Lymphoma|Diffuse Large B-Cell Lymphoma|Mesothelioma|Melanoma|Anemia, Refractory, with Excess of Blasts|Mantle-Cell Lymphoma|Waldenstrom Macroglobulinemia|Hairy Cell Leukemia|Lymphoproliferative Disorders|Multiple Myeloma|Breast Cancer|Skin Cancer|B-Cell Marginal Zone Lymphoma|Sarcoma|Gastrointestinal Stromal Tumors|Oncology Hematological Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03441555 |
M16-186 | P1 |
Completed |
Acute Myeloid Leukemia |
2021-01-25 |
25% |
2023-10-18 |
Primary Endpoints|Treatments |
NCT03563560 |
AML | P1 |
Completed |
Acute Myeloid Leukemia |
2020-03-31 |
32% |
2024-11-27 |
Primary Endpoints|Treatments |
JapicCTI-183964 |
JapicCTI-183964 | P1 |
Unknown |
Acute Myeloid Leukemia |
2020-03-31 |
|||
NCT03298984 |
TPI-ALV-101 | P1 |
Completed |
Acute Myeloid Leukemia |
2020-03-20 |
16% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT00094978 |
05-C-0010 | P1 |
Terminated |
Non-Small-Cell Lung Cancer|Mesothelioma|Esophageal Cancer |
2013-05-20 |
2019-03-21 |
Treatments |
|
NCT00735930 |
NCI-2009-00269 | P1 |
Completed |
Anemia, Refractory|Thrombocytopenia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Prolymphocytic Leukemia|Prolymphocytic B-Cell Leukemia |
2013-03-01 |
2019-03-18 |
Treatments |
|
NCT00101231 |
NCI-2012-01461 | P1 |
Terminated |
Acute Lymphoid Leukemia|Blast Crisis|Hypereosinophilic Syndrome|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Acute Basophilic Leukemia|Acute Eosinophilic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Erythroblastic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia |
2012-11-01 |
2019-03-21 |
Treatments |
|
NCT00377104 |
NCI-2009-00161 | P1 |
Terminated |
Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2012-11-01 |
2019-03-21 |
Treatments |
|
NCT00082784 |
NCI-2009-00058 | P1 |
Completed |
B-Cell Marginal Zone Lymphoma|Diffuse Large B-Cell Lymphoma|Multiple Myeloma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|Waldenstrom Macroglobulinemia|Mantle-Cell Lymphoma |
2012-10-01 |
2019-03-21 |
Treatments |
|
NCT00112684 |
NCI-2009-00135 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2012-07-01 |
2019-03-21 |
Treatments |
|
NCT00098579 |
NCI-2009-00048 | P1 |
Completed |
Sarcoma|Gastrointestinal Stromal Tumors |
2011-07-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00470197 |
NCI-2009-00243 | P1 |
Completed |
Acute Myelomonocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Megakaryoblastic Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Acute Erythroblastic Leukemia |
2011-01-01 |
2024-11-27 |
||
2017-001178-41 |
2017-001178-41 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-10-10 |
2022-03-13 |
Treatments |
|
NCT03593915 |
TPI-ALV-102 | P2 |
Terminated |
Preleukemia|Myelodysplastic Syndrome |
2021-08-16 |
13% |
2023-10-18 |
Primary Endpoints |
NCT03969420 |
TPI-ALV-202 | P2 |
Terminated |
Acute Myeloid Leukemia |
2021-04-22 |
36% |
2023-10-18 |
|
NCT04493099 |
NCI-2020-05266 | P2 |
Withdrawn |
Acute Myeloid Leukemia |
2020-10-12 |
2020-11-13 |
||
NCT02520011 |
TPI-ALV-201 | P2 |
Terminated |
Acute Myeloid Leukemia |
2020-02-12 |
70% |
2024-11-27 |
Primary Endpoints |
NCT00634244 |
NCI-2009-00520 | P2 |
Completed |
Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Acute Megakaryoblastic Leukemia |
2014-09-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00957905 |
NCI-2011-01405 | P2 |
Completed |
Testicular Cancer|Ovarian Cancer|Seminoma|Germinoma |
2014-08-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT01349972 |
NCI-2011-02587 | P2 |
Completed |
Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia |
2014-05-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00445341 |
07-C-0081 | P2 |
Completed |
Diffuse Large B-Cell Lymphoma|Mantle-Cell Lymphoma |
2012-04-30 |
2019-03-21 |
||
NCT00991952 |
NCI-2011-03825 | P2 |
Completed |
Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer |
2012-02-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
2006-006152-34 |
2006-006152-34 | P2 |
Completed |
Prolymphocytic B-Cell Leukemia|Prolymphocytic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2012-01-16 |
2022-03-12 |
Treatments |
|
NCT00464633 |
EFC6663 | P2 |
Completed |
Chronic Lymphoid Leukemia|Prolymphocytic B-Cell Leukemia|Lymphocytic Chronic B-Cell Leukemia|Prolymphocytic Leukemia |
2011-12-01 |
2019-03-21 |
Treatments |
|
NCT00112723 |
NCI-2011-01346 | P2 |
Terminated |
Immunoblastic Lymphadenopathy|Sezary Syndrome|Large-Cell Anaplastic Lymphoma|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|Adult T-Cell Leukemia-Lymphoma|Mycosis Fungoides|B-Cell Marginal Zone Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphomatoid Granulomatosis|Lymphocytic Chronic B-Cell Leukemia|Follicular Lymphoma|Multiple Myeloma|Waldenstrom Macroglobulinemia|Multiple Sclerosis|Mantle-Cell Lymphoma|Leukemia, Plasma Cell|Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia |
2011-02-01 |
2020-10-26 |
Primary Endpoints |